Boulding Mark Elliott, executive vice president and chief legal officer at PTC Therapeutics (PTCT), has filed 102 Form 4 transactions, all in the same company. The pattern is one-sided: zero open-market purchases and zero acquisitions, against $9.1 million in total sales. The most recent 17 filings are all sales or option exercises, with no buys in that window.
The recent trades cluster around option exercises paired with same-day sales, a common structure. On October 6, 2026, Elliott sold $27,909.60 in PTCT stock while exercising options valued at $17,147.70. The prior day, October 5, saw a larger sale of $104,881.14 matched with a $64,569.96 exercise. August 17 brought two sales totaling $204,127.26, offset by a $72,265.97 exercise. The heaviest activity came on July 6, with eight separate sales ranging from $26,010.30 to $87,448.76, plus two exercises worth $130,917.02 and $89,325.72. June 17 also had a $518,100 sale, the largest single transaction in the recent data, paired with a $396,055.40 exercise.
The dollar values of the sales consistently exceed the exercise values on each date, which is typical for a cashless exercise where shares are sold to cover the strike price and tax withholding. The absence of any open-market purchases in the entire filing history means Elliott has not added shares with his own money during this period. The sales are routine in structure, but the volume is steady: roughly one cluster per month from May through October 2026, with the largest single transaction being the $518,100 sale on June 17.
AI-assisted summary